- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Bilateral geographic atrophy (GA) secondary to age-related macular degeneration (AMD)
- Meeting Date: November 2025
- Public Summary Document (PSD) November 2025 PBAC Meeting - (PDF 989.8KB)
- Public Summary Document (PSD) November 2025 PBAC Meeting - (Word 262.2KB)
Pegcetacoplan – November 2025
Pegcetacoplan: Solution for intravitreal injection 15 mg in 0.1 mL (150 mg per mL); Syfovre® - November 2025
Last updated
5 November 2025